The RanBP9 antibody is designed to detect and study RanBP9, an evolutionarily conserved scaffold protein involved in diverse cellular processes . Key applications include:
Western blot (WB): Detects RanBP9 at ~78 kDa (full-length) and proteolytic fragments (e.g., ~60 kDa) .
Immunoprecipitation (IP): Identifies RanBP9 interaction partners, such as ATM kinase and Nucleolin .
Immunohistochemistry (IHC): Localizes RanBP9 in tissue samples, revealing nuclear-cytoplasmic shuttling dynamics .
ATM Phosphorylation: RanBP9 is phosphorylated by ATM at S181 and S603 following ionizing radiation (IR), facilitating its nuclear accumulation .
DDR Regulation: Silencing RanBP9 delays activation of ATM, Chk2, γH2AX, and p53, impairing homologous recombination repair and increasing IR-induced senescence/apoptosis .
| Parameter | Observation | Citation |
|---|---|---|
| Phosphorylation Sites | S181, S603 (ATM-dependent) | |
| γH2AX Dynamics | Reduced early (<4 h), elevated at 24 h | |
| HR Repair Efficiency | ↓ 50% in RanBP9-silenced cells |
RanBP9 overexpression increases Bax/Bcl-2 ratio, cytochrome c release, and mitochondrial ROS, promoting apoptosis in neuronal cells .
Co-localizes with transcription factor p73 in mitochondria, enhancing p73 stability and pro-apoptotic activity .
A 60 kDa RanBP9 fragment (N60) is elevated 6-fold in Alzheimer’s disease (AD) brains, correlating with amyloid-β peptide generation .
Combined full-length and N60 RanBP9 levels are 75% higher in AD vs. controls .
RanBP9 deficiency reduces ATM acetylation, sensitizing lung cancer cells to genotoxic therapies .
Tagged RanBP9 mouse models (V5-HA) reveal interactions with Nucleolin, a cancer therapeutic target .
Table 2: Anti-RanBP9 Antibody Specifications (ab205954)
| Parameter | Detail |
|---|---|
| Host Species | Rabbit |
| Applications | WB, IP |
| Predicted Band Size | 78 kDa |
| Optimal Lysate Loading | 50 µg (WB); 1 mg (IP) |
RanBP9-TT Mice: CRISPR/Cas9-engineered mice with C-terminal V5-HA tags enable high-sensitivity detection (e.g., liver samples) .
Tagged RanBP9 retains native interactions (e.g., with Nucleolin) and resolves antibody specificity issues .